NF110

NF110 is a P2X3 receptor antagonist (Ki = 36 nM) and inactive toward P2Y receptors stably expressed (IC50s > 10 M) . NF110 blocks alphabeta-methylene-ATP-induced currents (IC50 = 527 nM) in rat dorsal root ganglia neurons[1].

Product Specifications

CAS Number

[111150-22-2]

UNSPSC

12352005

Target

P2X Receptor

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/nf110.html

Purity

93.6

Solubility

H2O : 40 mg/mL (ultrasonic; warming)

Smiles

O=C(NC1=CC(C(NC2=CC=C(S(=O)(O[Na])=O)C=C2)=O)=CC(C(NC3=CC=C(S(=O)(O[Na])=O)C=C3)=O)=C1)NC4=CC(C(NC5=CC=C(S(=O)(O[Na])=O)C=C5)=O)=CC(C(NC6=CC=C(S(=O)(O[Na])=O)C=C6)=O)=C4

Molecular Formula

C41H28N6Na4O17S4

Molecular Weight

1096.91

References & Citations

[1]Hausmann R, et al. The suramin analog 4,4',4'',4'''- (carbonylbis (imino-5,1,3-benzenetriylbis (carbonylimino) ) ) tetra-kis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol. 2006;69 (6) :2058-2067.|[2]Dhar S, et al. Antitumour activity of suramin analogues in human tumour cell lines and primary cultures of tumour cells from patients. Eur J Cancer. 2000;36 (6) :803-809.|[3]Su L, et al. Identification of HMGA2 inhibitors by AlphaScreen-based ultra-high-throughput screening assays. Sci Rep. 2020;10 (1) :18850. Published 2020 Nov 2.